ResearcherSpanish National Cancer Research CentreActive in the last 2 years

Sara Barrambana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0200-7129; OpenAlex author ID A5035057723. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2025: 2 papers

Papers 2

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors. Co-author DOI 10.1016/j.addr.2025.115652 ↗
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. First author DOI 10.1073/pnas.2523039122 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vasiliki Liaki · 2 shared papers, 2025 · strength 0.55
- Paper Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors. DOI 10.1016/j.addr.2025.115652 ↗
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Carmen E. Guerra · 2 shared papers, 2025 · strength 0.55
- Paper Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors. DOI 10.1016/j.addr.2025.115652 ↗
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Francisco Sanchez Bueno · 1 shared paper, 2025 · strength 0.18
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Juan Carlos López-Gil · 1 shared paper, 2025 · strength 0.18
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Mariano Barbacid · 1 shared paper, 2025 · strength 0.18
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Bruno Sáinz · 1 shared paper, 2025 · strength 0.18
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗
Nelson Dusetti · 1 shared paper, 2025 · strength 0.18
- Paper A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. DOI 10.1073/pnas.2523039122 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.